These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15311111)

  • 1. Serial echocardiographic assessment of left ventricular mass: how blinded should readers be?
    Gosse P; de Simone G; Dubourg O; Guéret P; Schmieder R
    J Hypertens; 2004 Sep; 22(9):1813-8. PubMed ID: 15311111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiography in multicenter clinical trials: experience from the Treatment of Mild Hypertension Study.
    Grandits GA; Liebson PR; Dianzumba S; Prineas RJ
    Control Clin Trials; 1994 Oct; 15(5):395-410. PubMed ID: 8001359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial echocardiographic assessment of left ventricular mass.
    Stolk RP; Bots ML
    J Hypertens; 2005 Feb; 23(2):460-1; author reply 461-2. PubMed ID: 15662237
    [No Abstract]   [Full Text] [Related]  

  • 4. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.
    de Luca N; Mallion JM; O'Rourke MF; O'Brien E; Rahn KH; Trimarco B; Romero R; De Leeuw PW; Hitzenberger G; Battegay E; Duprez D; Sever P; Safar ME
    Am J Hypertens; 2004 Aug; 17(8):660-7. PubMed ID: 15323062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
    Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
    Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).
    Liebson PR; Grandits GA; Dianzumba S; Prineas RJ; Grimm RH; Neaton JD; Stamler J
    Circulation; 1995 Feb; 91(3):698-706. PubMed ID: 7828296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension.
    Gosse P; Guez D; Guéret P; Dubourg O; Beauchet A; de Cordoüe A; Barrandon S
    J Hypertens; 1998 Apr; 16(4):531-5. PubMed ID: 9797199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study.
    Gosse P; Dubourg O; Gueret P
    J Hypertens; 2003 Jan; 21(1):217-21. PubMed ID: 12544454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Echocardiography of left ventricular mass in patients with essential hypertension].
    Christensen KL; Fenger-Grøn M; Buus NH
    Ugeskr Laeger; 2009 Nov; 171(45):3252-5. PubMed ID: 19887054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
    Amador N; Encarnación JJ; Guízar JM; Rodríguez L; López M
    J Hum Hypertens; 2005 Apr; 19(4):277-83. PubMed ID: 15674406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of hypotensive drugs on left ventricular mass and diastolic function].
    Spring A; Haczyński J; Jołda-Mydłowska B; Witkowska M
    Pol Arch Med Wewn; 1995 Jul; 94(1):47-58. PubMed ID: 8524699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of comorbidities and medications on left ventricular mass regression after bariatric surgery.
    Syed M; Torosoff M; Rosati C; Alger S; Fein S
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):223-7. PubMed ID: 20433541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).
    Devereux RB; Dahlof B; Levy D; Pfeffer MA
    Am J Cardiol; 1996 Jul; 78(1):61-5. PubMed ID: 8712120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects.
    de Luca N; Asmar RG; London GM; O'Rourke MF; Safar ME;
    J Hypertens; 2004 Aug; 22(8):1623-30. PubMed ID: 15257187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
    Roush GC; Abdelfattah R; Song S; Kostis JB; Ernst ME; Sica DA
    J Hypertens; 2018 Jun; 36(6):1247-1255. PubMed ID: 29465713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
    Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-mode Echocardiographic Studies.
    de Simone G; Muiesan ML; Ganau A; Longhini C; Verdecchia P; Palmieri V; Agabiti-Rosei E; Mancia G
    J Hypertens; 1999 Dec; 17(12 Pt 2):1955-63. PubMed ID: 10703895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.